# Eternity Bioscience (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/eternity-bioscience-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 30 |
| Citations | 7,447 |
| City | Cranbury |
| Country | US |
| Description | Eternity Bioscience (United States) is a research organisation in Cranbury, US. OpenAlex records 227 works and 7,447 citations for it. 64 researchers list it as their most recent affiliation. |
| Homepage | https://www.eternitybioscience.com/ |
| OpenAlex ID | https://openalex.org/I4210153233 |
| Region | New Jersey |
| Researchers | 64 |
| ROR ID | https://ror.org/051ansx96 |
| Type | company |
| Works | 227 |

## University papers

- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma](https://scholariq.org/papers/phase-ii-trial-evaluating-the-clinical-and-biologic-effects-of-bevacizumab-in/)
- [Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis](https://scholariq.org/papers/recurrence-of-hepatocellular-carcinoma-after-liver-transplant-patterns-and/)
- [Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials](https://scholariq.org/papers/neoadjuvant-and-adjuvant-therapy-for-resectable-hepatocellular-carcinoma-review/)
- [Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/<i>neu</i>](https://scholariq.org/papers/herceptin-and-gemcitabine-for-metastatic-pancreatic-cancers-that-overexpress-her/)
- [Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia](https://scholariq.org/papers/successful-engraftment-of-gene-corrected-hematopoietic-stem-cells-in-non/)
- [A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer](https://scholariq.org/papers/a-phase-ii-and-biomarker-study-of-ramucirumab-a-human-monoclonal-antibody/)
- [Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial](https://scholariq.org/papers/ramucirumab-combined-with-folfox-as-front-line-therapy-for-advanced-esophageal/)
- [Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal](https://scholariq.org/papers/gene-therapy-for-infantile-malignant-osteopetrosis-review-of-pre-clinical/)

## University researchers

- [Jonathan D. Schwartz](https://scholariq.org/researchers/jonathan-d-schwartz/)

## University top topics

Showing 8 of 24.

- [Research Data Management Practices](https://scholariq.org/topics/research-data-management-practices/)
- [Environmental DNA in Biodiversity Studies](https://scholariq.org/topics/environmental-dna-in-biodiversity-studies/)
- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Spine and Intervertebral Disc Pathology](https://scholariq.org/topics/spine-and-intervertebral-disc-pathology/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Planarian Biology and Electrostimulation](https://scholariq.org/topics/planarian-biology-and-electrostimulation/)
- [Bone Tissue Engineering Materials](https://scholariq.org/topics/bone-tissue-engineering-materials/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.